Renaissance Technologies’s Immuneering IMRX Stock Holding History

Renaissance Technologies’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$384K	Sell	72,875 -79,425	-52%	-$407K	﹤0.01%	2712
2025 Q4	$1M	Buy	152,300 +117,300	+335%	+$753K	﹤0.01%	2276
2025 Q3	$245K	Buy	35,000 +16,800	+92%	+$87.2K	﹤0.01%	3079
2025 Q2	$61.3K	Buy	+18,200	New	+$31.2K	﹤0.01%	3366
2024 Q3	–	Sell	-349,100	Closed	-$447K	–	3699
2024 Q2	$447K	Buy	+349,100	New	+$574K	﹤0.01%	2746
2022 Q3	–	Sell	-25,537	Closed	-$138K	–	4210
2022 Q2	$138K	Sell	25,537 -32,063	-56%	-$171K	﹤0.01%	3759
2022 Q1	$373K	Buy	+57,600	New	+$553K	﹤0.01%	3364

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies's IMRX Position: Q1 2026 in Review

Renaissance Technologies reduced its Immuneering (IMRX) stake by 52% in Q1 2026, selling an estimated $407K and leaving 72,875 shares worth $384K. The position accounts for ﹤0.01% of the portfolio, ranked #2712.

Renaissance Technologies first reported a position in IMRX in Q1 2022 and has held it in 7 quarters since. The position peaked at $1M in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

Renaissance Technologies held 72,875 shares of Immuneering worth $384K as of Q1 2026.
Renaissance Technologies sold 79,425 Immuneering shares in Q1 2026, an estimated $407K.
Immuneering made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2712 holding.
Renaissance Technologies first reported a position in Immuneering in Q1 2022 and has held it in 7 quarters since.
Renaissance Technologies's Immuneering position peaked at $1M in Q4 2025.
95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.